10 August 2018
Visiongain has launched a new pharma report World Cancer-Treating Drugs Market Forecast 2017-2027: Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs
The future of the anti-cancer drugs market looks promising, as a number of new and innovative therapies are coming on to the market. In recent years there has been a remarkable improvement in the safety of products, with improvements of delivery of chemotherapy, among other techniques, reducing the toxicity of treatments.
The lead analyst of the report commented “’The anti-cancer treatments market will see strong growth driven by the ageing population, increasing demand of biological and targeted drug therapies, continuous patent expiry of major cancer drugs with generic competition eroding their share of the market and the rising uptake of biosimilars.
The anti-cancer drugs pipeline includes monoclonal antibodies, new classes of novel antineoplastics (including PARP inhibitors) and therapeutic vaccines. The launch of emerging classes, including immuno-oncologics, and combination therapies will offer potential breakthrough in cancer treatment. On a global context, the US will remain the largest market while emerging markets will see the highest rate of growth”
Leading companies featured in the report include AstraZeneca, Merck & Co., Inc. (Merck), Novartis, Amgen, Bristol-Myers Squibb (BMS), GlaxoSmithKline (GSK), Johnson & Johnson (J&J), Roche, Eli Lilly and Celgene.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.